Clinical trials: Cirrhosis Advanced
Hepatocellular Carcinoma, Liver Cancer
Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma
Hepatocellular cancer is the 6th most common seen disease in the world and the 3rd in cancer-related deaths. Liver transplantation is the primary curative treatment of HCC, as it eliminates liver cancer and underlying cirrhosis.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Advanced Adult Hepatocellular Carcinoma, Cirrhosis, Liver
- Trial name
- NCT04576572
- Where
- Turkey (Türkiye)
- Volunteers
- 424 people
- Sponsor
- Inonu University
Cirrhosis, Ascites
Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.
Effects of long term albumin administration on the cardiocirculatory and renal function and hepatic hemodynamics in patients with advanced cirrhosis and ascites.
- Trial name
- NCT00968695
- Testing
- Albumin
- Where
- 6 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Instituto Grifols, S.A.
Liver Cirrhosis
Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease
Protein-calorie malnutrition is frequently observed in patients with advanced liver cirrhosis. There have been continued interests in potential benefits of long-term oral branched-chain amino acid supplement in improving severity…
- Trial name
- BRAVE (NCT02837302)
- Testing
- Livact
- Where
- South Korea
- Volunteers
- 1,470 people
- Sponsor
- Kyungpook National University Hospital
Steatotic Liver Disease, Fibrosis of Liver
Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global adult population, 25-30% of whom suffer from metabolic dysfunction-associated steatohepatitis (MASH), increasing the risk of…
- Trial name
- MASLD-DIAB (NCT07270822)
- Testing
- Collaborative care pathways group, Control group without intervention
- Where
- 10 sites in France
- Volunteers
- 1,714 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis C
Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis
The purpose of the study is to determine if the combination of Daclatasvir, Sofosbuvir and Ribavirin for 12 or 16 weeks is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patients with advanced…
- Trial name
- NCT02319031
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 10 sites in Australia, France
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Liver Diseases, Alcoholic, Fibrosis
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients…
- Trial name
- SIPHON (NCT03308916)
- Testing
- transient elastography, Enhanced liver fibrosis test, Indirect serum markers of liver fibrosis
- Where
- Denmark
- Volunteers
- 6,500 people
- Sponsor
- Maja Thiele
Cholangitis, Secondary Biliary, Cholangiocarcinoma
Advanced Endoscopy During COVID-19
In this study, investigators aim to explore the status of advanced endoscopy in different endoscopy units all over the world.
- Conditions
- Cholangitis, Secondary Biliary, Cholangiocarcinoma, Obstructive Jaundice, Pancreas Cancer
- Trial name
- NCT04385147
- Testing
- Endoscopic management according to standard of care
- Where
- 5 sites in United States, Egypt and 3 more
- Volunteers
- 670 people
- Sponsor
- Al-Azhar University
Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
- Trial name
- NCT06777316
- Testing
- CGT4859
- Where
- 13 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Cogent Biosciences, Inc.
Advanced Adult Hepatocellular Carcinoma
Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy
The aim of this study is to determine the safety and efficacy of cabozantinib in the management of unresectable or metastatic hepatocellular carcinoma (HCC) with underlying Child-Pugh class B cirrhosis.
- Trial name
- NCT04497038
- Testing
- Cabozantinib
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan Rogel Cancer Center
Esophageal Varices, Non-alcoholic Fatty Liver
Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis
Non-alcoholic fatty liver disease (NAFLD) is defined as accumulation of fat in the liver which is not related to either alcohol excess or other causes such viral infection, immune-mediated, or medication related which can lead to…
- Conditions
- Esophageal Varices, Non-alcoholic Fatty Liver, Compensated Cirrhosis
- Trial name
- NCT05485714
- Testing
- Reviewing records retrospectively of patients undergoing screening endoscopy
- Where
- United Arab Emirates
- Volunteers
- 73 people
- Sponsor
- United Arab Emirates University
Heart Failure, Transplant; Failure, Heart
Shear Wave Elastography
In individuals needing a left ventricular assist device (LVAD), right heart failure (RHF) is a serious complication post-surgery, associated with worsened outcomes including mortality.
- Conditions
- Heart Failure, Transplant; Failure, Heart, Decompensated Heart Failure, Fibrosis, Liver
- Trial name
- NCT04493346
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Baylor Research Institute
Hepatitis B Virus Infection
Inhibition of HBV Replication and Biological Reversal of Cirrhosis (F3-F4) and HCC by Flavonoids
SB Flavonoids for Advanced Liver Disease ManagementSB Flavonoids represents a multi-target therapeutic composition engineered for the comprehensive management of Hepatitis (Acute and Chronic), Advanced Cirrhosis (F3)-(F4), and…
- Trial name
- Flavonoids (NCT07084948)
- Testing
- Flavonoid, Tenofovir
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 134 people
- Sponsor
- Trieu, Nguyen Thi, M.D.
Cirrhosis, Liver, Advanced Liver Fibrosis
Erlotinib for Hepatocellular Carcinoma Chemoprevention
This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.
- Trial name
- ECHO-B (NCT04172779)
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Intrahepatic Cholangiocarcinoma (Icc)
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (ICC), the second most prevalent primary malignant liver neoplasm, features highly aggressive biological behavior and dismal prognosis.
- Trial name
- LPHAIC for ICC (NCT07646717)
- Testing
- hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Liver Cirrhosis
Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis
The investigators aim to investigate the safety and efficacy of peripheral blood monocyte for the treatment of patients with advanced liver cirrhosis.
- Trial name
- NCT01503749
- Testing
- G-colony stimulating factor, Infusion of the mobilized monocyte cells
- Volunteers
- 9 people
- Sponsor
- Seoul National University Hospital
Cirrhosis
A Study to Detect Advanced Liver Disease Via AI-enabled Electrocardiogram
The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for…
- Trial name
- ADVANCE (NCT05782283)
- Testing
- ACE (AI-Cirrhosis-ECG) 2.0
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- Mayo Clinic
Cirrhosis, Ascites
Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis
The purpose of this study is to investigate the response to pioglitazone on the hepatic venous pressure gradient and peripheral vascular responsiveness to vasoconstrictors in patients with advanced (Child´s Grade B or C)…
- Conditions
- Cirrhosis, Ascites, Portal Hypertension
- Trial name
- NCT00570622
- Testing
- Pioglitazone
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Psychiatric Disorder, Psychiatric Hospitalization
Advanced Chronic Liver Disease Screening by Transient Elstography in Patients Hospitalised in a Psychiatric Unit
Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders. There are still many barriers to screening and linkage to care for patients having somatic illness.
- Conditions
- Psychiatric Disorder, Psychiatric Hospitalization, Advanced Chronic Liver Disease, Liver Fibrosis
- Trial name
- HEPSY (NCT05602870)
- Testing
- non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)
- Where
- France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Montpellier
Advanced Chronic Liver Disease, Surgery--Complications
Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery
The ELASTO-SURGERY study aims to evaluate the prognostic role of portal hypertension evaluated by non-invasive methods in predicting post-operative morbidity (at 90 days) and mortality (at 365 days) in patients with advanced…
- Trial name
- NCT04615091
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 250 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Liver Fibrosis, Hepatic Cirrhosis
The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.
- Trial name
- PECHORA (NCT07069725)
- Testing
- AZD2389, PET scan and radioligand
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- AstraZeneca